98%
921
2 minutes
20
Viral hepatitis is a leading cause of mortality and a global public health challenge that, until recently, has been largely neglected as a health priority. This study describes the prevalence of viral hepatitis B and C in asylum seekers and refugees who participated in screening across three cities in Northern Italy. The analysis highlights significant pitfalls in linkage and retention in care, as well as factors associated with continuing or discontinuing the healthcare pathways, controlling for WHO Region of origin, gender, age and study site. Hospital records provided demographic and clinical data. Screening for HBV, HCV, and HIV was conducted, followed by clinical management and vaccination where appropriate. Multinomial logistic regression identified distinct care pathways. Of 1,514 participants, 80.2 % underwent screening, with 87.3 % testing negative for all infections. For those with chronic infections, 20.8 % missed their first infectious disease consultation, and only 39.3 % were retained in care after one year. Among the 591 individuals (55.8 % of the total) eligible for HBV vaccination, 10.0 % (59 out of 591) actually received the vaccine. Seven distinct care pathways were identified, where significant differences were observed based on the region of origin and the specific study site, highlighting the impact of local healthcare infrastructure and support systems. This study highlights the critical need for innovative, intersectoral and community-based approaches that are responsive to migrants' needs and perspectives. Key recommendations include enhancing linkage to care, improving followup strategies, and establishing a robust national and European network to ensure continuity of care and to integrate public health efforts across the entire care pathway and deliver fair and equitable healthcare..
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11847036 | PMC |
http://dx.doi.org/10.1016/j.jmh.2025.100307 | DOI Listing |
Sex Transm Dis
September 2025
Departments of Global Health, Medicine, and Epidemiology, University of Washington (JN Wasserheit), National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (J Mermin and BP Stoner), and Rietmeijer Consulting (CA Rietmeijer).
mBio
September 2025
Fred Hutchinson Cancer Center, Vaccine and Infectious Disease Division, Seattle, Washington, USA.
Accurate timing estimates of when participants acquire HIV in HIV prevention trials are necessary for determining antibody levels at acquisition. The Antibody-Mediated Prevention (AMP) Studies showed that a passively administered broadly neutralizing antibody can prevent the acquisition of HIV from a neutralization-sensitive virus. We developed a pipeline for estimating the date of detectable HIV acquisition (DDA) in AMP Study participants using diagnostic and viral sequence data.
View Article and Find Full Text PDFJ Viral Hepat
October 2025
Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Discontinuing antivirals in chronic hepatitis B virus (HBV) 'e' antigen negative infection can enhance HBV surface antigen (HBsAg) loss but risks complications. We modelled the clinical impact of discontinuing antivirals in chronic HBV. We developed a Markov state model with Monte Carlo simulation of chronic HBV to compare continuation of antiviral therapy with 3 strategies of cessation and reinitiation for: (1) virologic relapse, (2) clinical relapse, or (3) hepatitis flare.
View Article and Find Full Text PDFJ Viral Hepat
October 2025
Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
Hepatitis B virus (HBV) infection is a global health challenge, with the World Health Organization (WHO) targeting its elimination by 2030. Jordan lacks sufficient data on HBV epidemiology, including prevalence, incidence and clearance. This study addresses these gaps through a retrospective analysis of HBV testing data from 40,268 individuals collected at Biolab Diagnostic Laboratories (2010-2024).
View Article and Find Full Text PDFBackground: Cytomegalovirus (CMV) viremia is a critical concern and known by the presence of the virus DNA in the blood, which poses sever risks and develops many complications in immuno-compromised patients. When CMV is untreated, it can cause pneumonitis, colitis, hepatitis, and encephalitis. Current diagnosis relies on molecular methods with qPCR as the preferred method.
View Article and Find Full Text PDF